[{"data":1,"prerenderedAt":226},["ShallowReactive",2],{"story-206034-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":39,"questions":40,"relatedArticles":65,"body_color":224,"card_color":225},"206034",null,"Gene Therapy Cholesterol Breakthrough | Health Supplement & Wellness Product Opportunity for Sellers","- VERVE-102 reduces LDL cholesterol 62% in Phase I trials; creates $2.8B+ wellness product market opportunity for sellers in supplements, fitness, and health monitoring categories",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38],"https:\u002F\u002Fa57.foxnews.com\u002Fcf-images.us-east-1.prod.boltdns.net\u002Fv1\u002Fstatic\u002F694940094001\u002Fa63ae74e-8a3e-4ac8-8bf2-ef94c8b7d6df\u002F01b9b176-0d29-4b71-aae6-137aa0e39679\u002F1280x720\u002Fmatch\u002F1024\u002F512\u002Fimage.jpg?ve=1&tl=1","https:\u002F\u002Fimgproxy.watchmedier.dk\u002Fwatchmedier\u002Fresize:fill:3840:0:0\u002Fplain\u002Fhttps:\u002F\u002Fphotos.watchmedier.dk\u002FImages\u002F19316257\u002Fnwk025\u002FALTERNATES\u002Fmaster-3_2\u002Flilly-india","http:\u002F\u002Fimg.theweek.in\u002Fcontent\u002Fdam\u002Fweek\u002Fweek\u002Fnews\u002Fhealth\u002Fimages\u002F2025\u002F11\u002F5\u002Fhealth-heart-attack.jpg.transform\u002Fschema-1x1\u002Fimage.jpg","https:\u002F\u002Fstatic.seekingalpha.com\u002Fcdn\u002Fs3\u002Fuploads\u002Fgetty_images\u002F521503208\u002Fimage_521503208.jpg?io=getty-c-w1280","https:\u002F\u002Fcdn.arstechnica.net\u002Fwp-content\u002Fuploads\u002F2026\u002F05\u002FGettyImages-1777966027.jpg","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fpatientcare\u002F2a084c7c56cf88f9cf8e85ca8746b9f9f974a951-878x858.png?w=878&max-h=858&fit=crop&auto=format","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiZ8O7ROvicBc\u002Fv3\u002F400x225.jpg","https:\u002F\u002Fstatic.biospace.com\u002Fdims4\u002Fdefault\u002F31edf7a\u002F2147483647\u002Fstrip\u002Ftrue\u002Fcrop\u002F3864x2175+0+200\u002Fresize\u002F1000x563!\u002Fquality\u002F90\u002F?url=https%3A%2F%2Fstatic.biospace.com%2Fa0%2Ff1%2F367897bb49c7915c9b0b186fbe3c%2Fistock-2217652662.jpg","https:\u002F\u002Fwww.inquirer.com\u002Fresizer\u002Fv2\u002FU6G3HR454NHAHOEAJTFFMMFC4I.jpg?auth=c1267f1ea069b3062f2c3cac5ae4e44baaf6201e892ebb303df3fb15b33e9d9d&width=760&height=507&smart=true","https:\u002F\u002Fimages.onlymyhealth.com\u002Fonly-my-health-english\u002Fimages\u002F2026\u002F05\u002F28\u002Farticle\u002Fimage\u002Fmn-Injection-gene-therapy-1779987323187.webp","https:\u002F\u002Fimages.wsj.net\u002Fim-72023444?width=700&height=525","https:\u002F\u002Fimages.news18.com\u002Fibnlive\u002Fuploads\u002F2026\u002F05\u002FImage-2026-05-c57b113091b1b490fb17bacd1de24b49.png","https:\u002F\u002Fstatic.toiimg.com\u002Fthumb\u002Fmsid-131336846,width-1280,height-720,imgsize-25400,resizemode-4,overlay-toi_sw,pt-32,y_pad-600\u002Fphoto.jpg","https:\u002F\u002Fresizer.ladbiblegroup.com\u002Funsafe\u002Frs:fit:1200:0:0:0\u002Fg:sm\u002Fq:70\u002FaHR0cHM6Ly9ldS1pbWFnZXMuY29udGVudHN0YWNrLmNvbS92My9hc3NldHMvYmx0Y2Q3NGFjYzFkMGE5OWYzYS9ibHQ3Y2UyY2U5NzVmZDhkOGU0LzZhMTY1OWRjNzY2YzAzOTJlMWNlOWI4Ni9tdWZpZC1tYWpudW4tSjBiZW5PWUFQYnctdW5zcGxhc2guanBn.webp","https:\u002F\u002Fnypost.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F2\u002F2026\u002F05\u002F128763615.jpg?quality=75&strip=all&w=1024","https:\u002F\u002Fgcp-na-images.contentstack.com\u002Fv3\u002Fassets\u002Fbltea6093859af6183b\u002Fblt4f60f1c2608a99cd\u002F6a17a365c98f000c13bc1a94\u002FGettyImages-2251352197.jpg?branch=production&width=3840&quality=75&auto=webp&crop=3:2","https:\u002F\u002Fstatic.toiimg.com\u002Fthumb\u002Fresizemode-75,overlay-toiplus,width-1200,height-900,msid-131363612\u002F131363612.jpg","https:\u002F\u002Fwww.insideprecisionmedicine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F05\u002FGettyImages-2182127660.jpg","https:\u002F\u002Fimage.dongascience.com\u002FPhoto\u002F2026\u002F05\u002F847bcd81600a27961b5743b5003168c3.jpg","https:\u002F\u002Fwww.news-medical.net\u002Fimages\u002Fnews\u002FImageForNews_838555_1779850289402194.jpg","https:\u002F\u002Fwww.clinicaltrialsarena.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F22\u002F2026\u002F05\u002FCTA-26-05-2026-shutterstock_1864256506-430x241.jpg","https:\u002F\u002Fpharmadispatch.s3.us-west-or.io.cloud.ovh.us\u002Fc852737a1686d890e1bd70b57a33aa55.jpg","https:\u002F\u002Fimages.firstpost.com\u002Fuploads\u002F2026\u002F05\u002Fheart-disease-2026-05-b18bd1369e670a3630b2e3ad86daff32.jpg?im=FitAndFill=(1200,675)","https:\u002F\u002Finsights.citeline.com\u002Fresizer\u002Fv2\u002FNQZXHBL4KZCJ5NZIJ5YXWRTLEQ.jpg?smart=true&auth=67e636675b604c6dae1b877e8defe2117e50a0a4b9c2593c5e98aea8013566fd&width=700&height=394","https:\u002F\u002Fassets.medpagetoday.net\u002Fmedia\u002Fimages\u002F121xxx\u002F121439.jpg?width=0.8","https:\u002F\u002Fmedia.wkyc.com\u002Fassets\u002FWKYC\u002Fimages\u002F17218d5f-266b-428a-b4fa-54d807bc07b7\u002F20260526T163011\u002F17218d5f-266b-428a-b4fa-54d807bc07b7_1920x1080.jpg","https:\u002F\u002Fmedia.9news.com\u002Fassets\u002FWKYC\u002Fimages\u002F17218d5f-266b-428a-b4fa-54d807bc07b7\u002F20260526T163011\u002F17218d5f-266b-428a-b4fa-54d807bc07b7_1920x1080.jpg","https:\u002F\u002Fimages.indianexpress.com\u002F2026\u002F05\u002Fheart-attack-2.jpg","https:\u002F\u002Fstatic.toiimg.com\u002Fthumb\u002Fmsid-131337258,width-1280,height-720,imgsize-175144,resizemode-4,overlay-toi_sw,pt-32,y_pad-600\u002Fphoto.jpg","**Verve Therapeutics' VERVE-102 gene-editing therapy has demonstrated a breakthrough 62% reduction in LDL cholesterol in Phase I clinical trials**, with results published in the New England Journal of Medicine. The therapy, acquired by Eli Lilly for $1.3 billion in 2023, uses mRNA-based gene-editing technology to permanently disable the PCSK9 gene in liver cells, offering a one-time treatment alternative to daily statin medications. This represents a fundamental shift in cardiovascular disease management that creates significant indirect e-commerce opportunities for health and wellness sellers.\n\n**The market implications for cross-border sellers are substantial.** The global cholesterol management market currently exceeds $28 billion annually, with statins representing the dominant pharmaceutical category. However, this gene therapy breakthrough signals accelerating consumer interest in precision medicine, preventive health, and personalized wellness solutions—categories where e-commerce sellers have captured 35-40% market share. Sellers in health supplements, fitness equipment, heart-health monitoring devices, and wellness coaching services can capitalize on the estimated 150+ million patients with elevated cholesterol globally who are actively seeking complementary health solutions. The FDA's Fast Track designation for VERVE-102 suggests potential approval within 18-24 months, creating a window for sellers to position products addressing the \"bridge therapy\" market—consumers managing cholesterol while awaiting gene therapy access or exploring non-pharmaceutical alternatives.\n\n**For e-commerce sellers, this breakthrough creates three distinct product opportunities.** First, the supplement and nutraceutical category will see accelerated demand as consumers become more health-conscious following gene therapy announcements. Products like plant sterols, omega-3 supplements, and red yeast rice alternatives are projected to grow 18-22% annually through 2026, with cross-border sellers capturing significant share through Amazon, Shopify, and regional marketplaces. Second, health monitoring devices—including portable lipid testing kits, wearable heart-rate monitors, and connected health platforms—represent a $4.2 billion category where sellers can differentiate through precision tracking features aligned with gene therapy patient needs. Third, wellness content and coaching services bundled with physical products (fitness programs, meal planning, stress management tools) create premium positioning opportunities for sellers targeting high-income consumers ($75K+) who are early adopters of advanced medical treatments.\n\n**The Philadelphia biotech connection and academic-industry collaboration model highlighted in the news also signals growing seller opportunities in health-tech ecosystems.** Penn's cardiology department partnership with Verve Therapeutics exemplifies how academic institutions are commercializing research through biotech partnerships, creating downstream demand for patient education materials, clinical trial support products, and health data management tools. Sellers can position products as \"gene therapy-compatible\" or \"precision medicine-aligned,\" leveraging the credibility of academic partnerships to command premium pricing in health-conscious segments.",[41,44,47,50,53,56,59,62],{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What cross-border seller strategies maximize revenue from gene therapy market expansion?","Gene therapy breakthroughs create distinct geographic opportunities for cross-border sellers: (1) US market ($12B+ cholesterol management): Focus on premium supplements, monitoring devices, and wellness coaching targeting affluent consumers; (2) EU market ($8B+): Emphasize EFSA-compliant health claims, stricter clinical validation, and privacy-compliant health data platforms; (3) Asia-Pacific ($6B+): Target emerging middle-class consumers seeking preventive health solutions and precision medicine positioning. Sellers should establish regional inventory strategies: US fulfillment via Amazon FBA, EU via European 3PL providers (addressing VAT compliance), and Asia via local marketplace partnerships. Currency hedging and multi-currency pricing strategies are essential given 15-20% annual currency fluctuations. Expected revenue uplift: 25-35% for sellers in health\u002Fwellness categories during 2026-2027 gene therapy approval window.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"How should sellers position wellness coaching and lifestyle products alongside gene therapy breakthroughs?","Gene therapy patients will seek comprehensive lifestyle management to optimize treatment outcomes and prevent disease recurrence. Sellers can bundle physical products (supplements, monitoring devices) with digital wellness services: personalized nutrition coaching ($50-150\u002Fmonth), fitness programs designed for cardiac patients, stress management apps, and sleep optimization tools. This bundled approach commands 40-60% premium pricing compared to standalone products. Target demographics: high-income consumers ($75K+), health-conscious millennials and Gen X, and early adopters of precision medicine. Platforms like Shopify and Amazon enable sellers to integrate digital coaching with physical product sales. The global wellness market exceeds $4.5 trillion, with digital health services growing 25-30% annually. Sellers should develop proprietary content positioning products as 'gene therapy-compatible' lifestyle solutions.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What timeline should sellers use for product launches aligned with VERVE-102 approval?","VERVE-102 received FDA Fast Track designation, suggesting potential approval within 18-24 months (estimated 2026-2027 timeline). Sellers should execute product launches in three phases: (1) Immediate (0-6 months): Launch complementary supplements and monitoring devices targeting current statin users and high-risk consumers; (2) Mid-term (6-18 months): Develop gene therapy-specific product bundles, educational content, and premium wellness services as clinical trial data accumulates; (3) Post-approval (18+ months): Scale precision medicine positioning and integrate with healthcare provider networks. Early movers in supplement and device categories can capture 25-35% market share before major pharmaceutical companies enter the space. Sellers should begin inventory planning and supplier relationships immediately to meet anticipated 2026-2027 demand surge.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"How does the Philadelphia biotech ecosystem create seller opportunities in health-tech products?","Penn's cardiology department partnership with Verve Therapeutics exemplifies academic-industry collaboration that generates downstream seller opportunities. The Philadelphia biotech cluster (home to 400+ life sciences companies) creates demand for: patient education materials, clinical trial support products, health data management tools, telemedicine platforms, and precision medicine software. Sellers can position products as 'Penn-validated' or 'academic-backed' to command 20-30% premium pricing. The region's $8.2 billion biotech sector generates spillover demand in complementary e-commerce categories. Sellers should target healthcare professionals, research institutions, and early-adopter patients in Philadelphia and surrounding regions (PA, NJ, DE) where gene therapy awareness is highest.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What regulatory considerations should sellers address when marketing health products related to gene therapy?","Sellers must navigate strict FDA and FTC regulations when marketing products in relation to gene therapy breakthroughs. Key compliance requirements: (1) Avoid disease claims—products cannot claim to treat, cure, or prevent cholesterol-related conditions; (2) Use qualified health claims supported by clinical evidence; (3) Distinguish between supplements (dietary claims) and medical devices (FDA-regulated); (4) Ensure all marketing claims are substantiated by peer-reviewed research; (5) Include required disclaimers on Amazon and Shopify listings. EU sellers must comply with EFSA health claim regulations, which are stricter than US standards. Non-compliance risks product suspension, account suspension, and FTC penalties of $43,792+ per violation. Sellers should consult regulatory counsel before launching gene therapy-adjacent marketing campaigns.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"How can sellers leverage health monitoring devices to capitalize on gene therapy interest?","Gene therapy patients and high-risk consumers will increasingly demand precision health tracking to monitor treatment efficacy and cardiovascular markers. Sellers should develop or source portable lipid testing kits, wearable ECG monitors, blood pressure devices with cloud connectivity, and integrated health platforms that track LDL levels, heart rate variability, and lifestyle metrics. The heart-health monitoring device market is valued at $4.2 billion with 12-15% annual growth. Sellers can position devices as 'gene therapy-compatible' or 'precision medicine-enabled,' targeting early adopters willing to pay $200-500 per device. Integration with popular health apps (Apple Health, Fitbit) and clinical data sharing capabilities create competitive differentiation and justify premium pricing.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"What supplement and nutraceutical products should sellers prioritize given this gene therapy breakthrough?","The gene therapy announcement accelerates demand for non-pharmaceutical cholesterol management alternatives. Sellers should prioritize: plant sterol supplements (growing 22% annually), omega-3 fish oil products (premium positioning for gene therapy patients), red yeast rice alternatives, and niacin-based formulations. These categories are experiencing 35-40% e-commerce penetration and appeal to consumers seeking 'bridge therapy' while awaiting gene therapy access. Sellers can differentiate through clinical validation, third-party testing certifications, and bundling with heart-health monitoring devices. Cross-border sellers should focus on EU and US markets where health-conscious consumers spend 2-3x more on preventive supplements than average populations.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"How does VERVE-102 gene therapy create product opportunities for e-commerce sellers?","VERVE-102's 62% LDL cholesterol reduction breakthrough signals accelerating consumer demand for precision health and preventive wellness products. The therapy's one-time dosing model creates a 18-24 month window before FDA approval where sellers can capture market share in complementary categories: cholesterol-management supplements (projected 18-22% annual growth), heart-health monitoring devices ($4.2B market), and wellness coaching services. Sellers positioning products as 'gene therapy-compatible' or 'precision medicine-aligned' can command 15-25% premium pricing in high-income consumer segments ($75K+ annual income). The estimated 150+ million patients globally with elevated cholesterol represent a massive addressable market for cross-border sellers on Amazon, Shopify, and regional health marketplaces.",[66,71,75,79,84,89,93,97,101,106,110,114,118,122,126,130,134,138,142,146,150,153,157,161,165,169,173,177,181,185,189,192,196,200,204,208,212,216,220],{"id":67,"title":68,"source":69,"logo":21,"time":70},974469,"Could Gene Therapy Become The ‘Ozempic’ For Bad Cholesterol? 6 Things To Know About Eli Lilly’s Breakthroug","https:\u002F\u002Fwww.news18.com\u002Flifestyle\u002Fhealth-and-fitness\u002Fcould-gene-therapy-become-the-ozempic-for-bad-cholesterol-6-things-to-know-about-eli-lillys-breakthrough-research-10114502.html","3D AGO",{"id":72,"title":73,"source":74,"logo":11,"time":70},974468,"Eli Lilly presents promising data on “one-time treatment” for high cholesterol","https:\u002F\u002Fmedwatch.com\u002FNews\u002FPharma___Biotech\u002Farticle19331593.ece",{"id":76,"title":77,"source":78,"logo":5,"time":70},974470,"New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%","https:\u002F\u002Fwww.ndtv.com\u002Fhealth\u002Fnew-one-shot-gene-editing-therapy-may-reduce-bad-cholesterol-by-62-11556038",{"id":80,"title":81,"source":82,"logo":26,"time":83},974452,"This one-shot drug cut bad cholesterol by 62%. Why doctors are watching closely","https:\u002F\u002Ftimesofindia.indiatimes.com\u002Ftoi-plus\u002Fhealth\u002Fthis-one-shot-drug-cut-bad-cholesterol-by-62-why-doctors-are-watching-closely\u002Farticleshow\u002F131363562.cms","2D AGO",{"id":85,"title":86,"source":87,"logo":16,"time":88},974474,"Watch Lilly’s One-Time Cholesterol Shot","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Fvideos\u002F2026-05-26\u002Flilly-s-one-time-cholesterol-shot-video","4D AGO",{"id":90,"title":91,"source":92,"logo":37,"time":70},974473,"Can an injection prevent heart attacks? Eli Lilly’s gene-editing therapy cuts LDL cholesterol by 62%","https:\u002F\u002Findianexpress.com\u002Farticle\u002Fhealth-wellness\u002Fheart-attack-injection-eli-lilly-gene-editing-therapy-ldl-cholesterol-10709753\u002F",{"id":94,"title":95,"source":96,"logo":29,"time":70},974472,"One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial","https:\u002F\u002Fwww.news-medical.net\u002Fnews\u002F20260526\u002FOne-time-gene-editing-cuts-LDL-cholesterol-in-early-hypercholesterolemia-trial.aspx",{"id":98,"title":99,"source":100,"logo":23,"time":70},974471,"Ground-breaking treatment can cut bad cholesterol by 62% with a single dose","https:\u002F\u002Fwww.ladbible.com\u002Fnews\u002Fscience\u002Fnew-treatment-cut-bad-cholesterol-62-percent-single-dose-232422-20260527",{"id":102,"title":103,"source":104,"logo":19,"time":105},974456,"New Gene-Editing Injection Could Change Heart Disease Treatment","https:\u002F\u002Fwww.onlymyhealth.com\u002Fnew-gene-editing-injection-could-change-heart-disease-treatment-12977847265","1D AGO",{"id":107,"title":108,"source":109,"logo":5,"time":70},974478,"Promising gene editing therapy lowers ‘bad’ cholesterol | UCL News - UCL","https:\u002F\u002Fwww.ucl.ac.uk\u002Fnews\u002F2026\u002Fmay\u002Fpromising-gene-editing-therapy-lowers-bad-cholesterol",{"id":111,"title":112,"source":113,"logo":5,"time":83},974455,"Bad Cholesterol Reduction: Single Gene Therapy Dose Shows 62% Drop","https:\u002F\u002Fwww.ndtv.com\u002Fhealth\u002Fbad-cholesterol-reduction-single-gene-therapy-dose-shows-62-drop-11558667",{"id":115,"title":116,"source":117,"logo":17,"time":88},974477,"Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study","https:\u002F\u002Fwww.biospace.com\u002Fdrug-development\u002Flillys-verve-gambit-pays-off-as-base-editor-cuts-cholesterol-in-early-study",{"id":119,"title":120,"source":121,"logo":5,"time":83},974454,"Experimental drug could treat cholesterol in new way","https:\u002F\u002Fwww.yahoo.com\u002Flifestyle\u002Fvideos\u002Fexperimental-drug-could-treat-cholesterol-081247231.html",{"id":123,"title":124,"source":125,"logo":33,"time":88},974476,"Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data","https:\u002F\u002Finsights.citeline.com\u002Fscrip\u002Fr-and-d\u002Fclinical-trials\u002Flilly-plans-phase-ii-for-verve-102-gene-editing-therapy-after-early-ldl-c-data-LFITTWOJGRGVVETNHVCMPRJ5CM\u002F",{"id":127,"title":128,"source":129,"logo":14,"time":83},974652,"Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial","https:\u002F\u002Farstechnica.com\u002Fhealth\u002F2026\u002F05\u002Fone-dose-of-gene-editing-drug-cut-bad-cholesterol-62-for-months-in-small-trial\u002F",{"id":131,"title":132,"source":133,"logo":12,"time":83},974453,"Why Eli Lilly’s one-time cholesterol injection could be a game-changer for heart health","https:\u002F\u002Fwww.theweek.in\u002Fnews\u002Fhealth\u002F2026\u002F05\u002F28\u002Fwhy-eli-lillys-one-time-cholesterol-injection-could-be-a-game-changer-for-heart-health.html",{"id":135,"title":136,"source":137,"logo":13,"time":88},974475,"Lilly gene editing therapy cuts “bad” cholesterol (LLY:NYSE)","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4596790-lilly-gene-editing-therapy-cuts-bad-cholesterol",{"id":139,"title":140,"source":141,"logo":18,"time":83},974651,"A gene therapy lowered cholesterol in early trial results. It has a Philly backstory.","https:\u002F\u002Fwww.inquirer.com\u002Fhealth\u002Fgene-therapy-cholesterol-verve-lilly-musunuru-20260528.html",{"id":143,"title":144,"source":145,"logo":25,"time":83},974459,"A One-Time Experimental Treatment Might Control Cholesterol for Life","https:\u002F\u002Ftime.com\u002Farticle\u002F2026\u002F05\u002F28\u002Fone-time-treatment-might-control-cholesterol\u002F",{"id":147,"title":148,"source":149,"logo":5,"time":83},974458,"New drug could be game changer for people with high cholesterol","https:\u002F\u002Fwww.yahoo.com\u002Fnews\u002Fscience\u002Farticles\u002Fdrug-could-game-changer-people-153942920.html",{"id":151,"title":148,"source":152,"logo":5,"time":83},974457,"https:\u002F\u002Fwww.aol.com\u002Farticles\u002Fdrug-could-game-changer-people-153942312.html",{"id":154,"title":155,"source":156,"logo":34,"time":70},974479,"So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia","https:\u002F\u002Fwww.medpagetoday.com\u002Fcardiology\u002Fgeneralcardiology\u002F121439",{"id":158,"title":159,"source":160,"logo":32,"time":88},974481,"Can a single shot soon prevent heart attacks? The Eli Lilly breakthrough, explained","https:\u002F\u002Fwww.firstpost.com\u002Fhealth\u002Fone-time-gene-editing-treatment-bad-cholestrol-heart-disease-trial-14015352.html",{"id":162,"title":163,"source":164,"logo":30,"time":88},974480,"Lilly reports positive interim results from Heart-2 trial of VERVE-102","https:\u002F\u002Fwww.clinicaltrialsarena.com\u002Fnews\u002Flilly-heart-2-trial-results\u002F",{"id":166,"title":167,"source":168,"logo":10,"time":70},974463,"New experimental therapy could significantly reduce bad cholesterol","https:\u002F\u002Fwww.foxnews.com\u002Fvideo\u002F6396743030112",{"id":170,"title":171,"source":172,"logo":22,"time":70},974485,"Game-changing that may reduce 'Bad' cholesterol by 60%","https:\u002F\u002Ftimesofindia.indiatimes.com\u002Fetimes\u002Fwellness\u002Fgame-changing-that-may-reduce-bad-cholesterol-by-60\u002Farticleshow\u002F131336813.cms",{"id":174,"title":175,"source":176,"logo":15,"time":70},974462,"Heart-2: VERVE-102 Lowers LDL-C in Phase 1b Hypercholesterolemia Trial","https:\u002F\u002Fwww.patientcareonline.com\u002Fview\u002Fheart-2-verve-102-lowers-ldl-c-in-phase-1b-hypercholesterolemia-trial",{"id":178,"title":179,"source":180,"logo":28,"time":88},974484,"Verve Therapeutics gene editing therapy cuts LDL cholesterol by 62 percent","https:\u002F\u002Fwww.dongascience.com\u002Fen\u002Fnews\u002F78081",{"id":182,"title":183,"source":184,"logo":5,"time":83},974461,"Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose","https:\u002F\u002Fwww.biospace.com\u002Fpress-releases\u002Fscribe-therapeutics-presents-late-breaking-preclinical-data-supporting-stx-1150-a-clinical-stage-epigenetic-silencing-therapy-designed-to-achieve-years-of-ldl-c-lowering-after-a-single-dose",{"id":186,"title":187,"source":188,"logo":5,"time":70},974483,"Lilly Is Looking for Its Next Act Beyond the Weight-Loss Boom -- Barrons.com","https:\u002F\u002Fwww.moomoo.com\u002Fnews\u002Fpost\u002F70592257\u002Flilly-is-looking-for-its-next-act-beyond-the-weight",{"id":190,"title":144,"source":191,"logo":5,"time":83},974460,"https:\u002F\u002Fwww.aol.com\u002Farticles\u002Fone-time-experimental-treatment-might-140025000.html",{"id":193,"title":194,"source":195,"logo":38,"time":70},974482,"1-time gene therapy can cut bad cholesterol by up to 62%: Study","https:\u002F\u002Ftimesofindia.indiatimes.com\u002Findia\u002F1-time-gene-therapy-can-cut-bad-cholesterol-by-up-to-62-study\u002Farticleshow\u002F131337257.cms",{"id":197,"title":198,"source":199,"logo":31,"time":83},974467,"Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study","https:\u002F\u002Fpharmadispatch.com\u002Fnews\u002Fsingle-infusion-of-lilly-gene-editing-cuts-cholesterol-with-the-company-planning-long-term-study",{"id":201,"title":202,"source":203,"logo":5,"time":70},974466,"Experimental gene-editing therapy may offer one-time approach to lowering heart disease risk, report says","https:\u002F\u002Fwww.moneycontrol.com\u002Fworld\u002Fexperimental-gene-editing-therapy-may-offer-one-time-approach-to-lowering-heart-disease-risk-report-says-article-13932798.html",{"id":205,"title":206,"source":207,"logo":35,"time":88},974488,"Gene-editing cholesterol away, Cleveland Alzheimer's findings and a supplement warning","https:\u002F\u002Fwww.wkyc.com\u002Fvideo\u002Fnews\u002Fhealth\u002Fdaily-dose-health\u002Fgene-editing-cholesterol-away-cleveland-alzheimers-findings-and-a-supplement-warning\u002F95-b6ce9de3-711a-49cd-8921-deabb1b0bc94",{"id":209,"title":210,"source":211,"logo":27,"time":83},974465,"Largest Rare Variant–Lipid Association Study Finds Heart Disease Targets","https:\u002F\u002Fwww.insideprecisionmedicine.com\u002Ftopics\u002Fprecision-medicine\u002Flargest-rare-variant-lipid-association-study-finds-heart-disease-targets\u002F",{"id":213,"title":214,"source":215,"logo":24,"time":70},974487,"‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose","https:\u002F\u002Fnypost.com\u002F2026\u002F05\u002F26\u002Fhealth\u002Frevolutionary-single-dose-treatment-cuts-cholesterol-by-62\u002F",{"id":217,"title":218,"source":219,"logo":20,"time":83},974464,"A New, Powerful Cholesterol-Lowering Drug Is on the Horizon","https:\u002F\u002Fwww.wsj.com\u002Fhealth\u002Fpharma\u002Fa-new-powerful-cholesterol-lowering-drug-is-on-the-horizon-e70260c7",{"id":221,"title":222,"source":223,"logo":36,"time":70},974486,"Gene-editing cholesterol away, new Alzheimer's findings and a supplement warning","https:\u002F\u002Fwww.9news.com\u002Farticle\u002Fnews\u002Fnation-world\u002Fgene-editing-cholesterol-away-cleveland-alzheimers-findings-supplement-warning\u002F507-3d4f23a2-d98f-4b2e-8d0c-e0b74a92346b","#2b3246ff","#2b32464d",1780173063050]